[go: up one dir, main page]

DE60139134D1 - Diuretikum oder sulfonylharnstoff zur benutzung in antiviraler behandlung - Google Patents

Diuretikum oder sulfonylharnstoff zur benutzung in antiviraler behandlung

Info

Publication number
DE60139134D1
DE60139134D1 DE60139134T DE60139134T DE60139134D1 DE 60139134 D1 DE60139134 D1 DE 60139134D1 DE 60139134 T DE60139134 T DE 60139134T DE 60139134 T DE60139134 T DE 60139134T DE 60139134 D1 DE60139134 D1 DE 60139134D1
Authority
DE
Germany
Prior art keywords
diethetics
sulfonyl urea
antiviral treatment
treatment
diuretic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60139134T
Other languages
English (en)
Inventor
Ian Stuart Henderson Mo Pardoe
Christopher Edward Hartley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henderson Morley Research and Development Ltd
Original Assignee
Henderson Morley Research and Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0023199A external-priority patent/GB2367242B/en
Priority claimed from GB0104031A external-priority patent/GB0104031D0/en
Priority claimed from GB0104030A external-priority patent/GB0104030D0/en
Priority claimed from GB0114947A external-priority patent/GB2376628B/en
Application filed by Henderson Morley Research and Development Ltd filed Critical Henderson Morley Research and Development Ltd
Application granted granted Critical
Publication of DE60139134D1 publication Critical patent/DE60139134D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60139134T 2000-09-21 2001-09-21 Diuretikum oder sulfonylharnstoff zur benutzung in antiviraler behandlung Expired - Fee Related DE60139134D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0023199A GB2367242B (en) 2000-09-21 2000-09-21 Antiviral treatment
GB0104031A GB0104031D0 (en) 2001-02-19 2001-02-19 Antiviral treatment
GB0104030A GB0104030D0 (en) 2001-02-19 2001-02-19 Antiviral treatment
GB0114947A GB2376628B (en) 2001-06-19 2001-06-19 Treatment of DNA viral infections in cats
PCT/GB2001/004206 WO2002024207A1 (en) 2000-09-21 2001-09-21 Diuretic or sulphonylurea for use in antiviral treatment

Publications (1)

Publication Number Publication Date
DE60139134D1 true DE60139134D1 (de) 2009-08-13

Family

ID=27447886

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60139134T Expired - Fee Related DE60139134D1 (de) 2000-09-21 2001-09-21 Diuretikum oder sulfonylharnstoff zur benutzung in antiviraler behandlung

Country Status (6)

Country Link
US (1) US20040034016A1 (de)
EP (1) EP1322316B1 (de)
AT (1) ATE435019T1 (de)
AU (1) AU2001287907A1 (de)
DE (1) DE60139134D1 (de)
WO (1) WO2002024207A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049300A2 (en) * 1999-12-30 2001-07-12 Henderson Morley Research And Development Limited Combinations for the treatment of dna viral infections comprising a loop diuretic and lithium
WO2004071506A1 (en) 2003-02-12 2004-08-26 Georgetown University Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
WO2005023182A2 (en) 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
EP1855688A4 (de) 2005-02-24 2011-09-14 Nicox Sa Stickoxidverstärkende diuretische verbindungen, zusammensetzungen und verwendungsverfahren
GB0517840D0 (en) * 2005-09-02 2005-10-12 Henderson Morley Plc Topical anti viral formulations
GB0517838D0 (en) * 2005-09-02 2005-10-12 Henderson Morley Plc Transdermal active principle delivery means
US10188617B2 (en) 2013-03-12 2019-01-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of cellular DNA repair activity to intercept malignancy
WO2015148684A2 (en) 2014-03-26 2015-10-01 Gutierrez Enrique G Compositions and related methods for treating and preventing viral and retroviral infections
US11260074B2 (en) 2014-03-26 2022-03-01 Enrique G. Gutierrez Compositions and related methods for reconstituting the immune system of a subject

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5855411A (ja) * 1981-09-28 1983-04-01 Nitto Electric Ind Co Ltd 基剤組成物および外用医薬組成物
US5196410A (en) * 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
JPH07179347A (ja) * 1993-12-21 1995-07-18 Showa Shell Sekiyu Kk 抗ウイルス組成物
US5686100A (en) * 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
FR2770925B1 (fr) * 1997-11-12 2000-01-07 Sagem Procede de transmission de telecommandes
WO2001049300A2 (en) * 1999-12-30 2001-07-12 Henderson Morley Research And Development Limited Combinations for the treatment of dna viral infections comprising a loop diuretic and lithium
ES2218254T3 (es) * 1999-12-30 2004-11-16 Henderson Morley Research And Development Limited Combinaciones de glicosidos cardiacos con diureticos de asa para el tratamiento de infecciones viricas de adn.

Also Published As

Publication number Publication date
US20040034016A1 (en) 2004-02-19
ATE435019T1 (de) 2009-07-15
EP1322316B1 (de) 2009-07-01
WO2002024207A1 (en) 2002-03-28
EP1322316A1 (de) 2003-07-02
AU2001287907A1 (en) 2002-04-02

Similar Documents

Publication Publication Date Title
BRPI0411900A (pt) compostos antivirais e métodos
ME01222B (me) Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera
DK1265889T3 (da) Lægemidler imod virussygdomme
FI893962A7 (fi) HIV-proteaasi-inhibiittoreita, jotka ovat hyödyllisiä AIDS:in hoidossa
PT1242425E (pt) Compostos de n-(5,7-dimetoxi¬1,2,4|triazolo1,5-a|pirimidin-2-il) arilsulfonamida e sua utilizacao como herbicidas
IS2714B (is) Uppsöfnun í frumu á phosphomate hliðstæðum á HIV próteasa hindrandi efnasamböndum
FI906212A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat käyttökelpoisia AIDSin hoidossa
DE60317060D1 (de) Mikrobizide pyrimidine oder triazine zur vorbeugung der sexuellen übertragung von hiv
DK0634927T3 (da) Behandling og profylakse af sygdomme forårsaget af parasitter eller bakterier
DE60219292D1 (de) Pyrazolderivate zur behandlung von hiv
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
ATE418554T1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
ID26043A (id) Turunan-turunan 1,3,5-triazina tertrisubstitusi untuk pengobatan infeksi-infeksi hiv
ATE249219T1 (de) Antivirale verbindungen
BR0105212B1 (pt) artigo descartável do vestuário.
DE60100625D1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
DK0975327T3 (da) Anvendelse af 5HT3-antagonister til befordring af tarmudskylning
DK1299354T3 (da) Faktor VIIA hæmmende (thio)urea-derivater, fremstilling og anvendelse deraf
DE60218633D1 (de) Inhibitoren von cruzipain und anderen cysteinproteasen
FI923158A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoidossa
DE69928779D1 (de) Nichtnukleoside reverse transkriptase-hemmer zur behandlung von hiv-infektion
DE60139134D1 (de) Diuretikum oder sulfonylharnstoff zur benutzung in antiviraler behandlung
DK1242119T3 (da) Kombinationer til behandling af DNA-virale infektioner omfattende et loop-diuretikum og et hjerteglycosid
DE60015568D1 (de) Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee